Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
Authors:
- Gillian BoothGBGillian Booth
- Lorraine LipscombeLLLorraine Lipscombe
- Sonia ButaliaSBSonia Butalia
- Kaberi DasguptaKDKaberi Dasgupta
- Dean EurichDEDean Eurich
- Ronald GoldenbergRGRonald Goldenberg
- Nadia KhanNKNadia Khan
- Lori MacCallumLMLori MacCallum
- Baiju ShahBSBaiju Shah
- Scot SimpsonSSScot Simpson
- Robyn L. HouldenRHRobyn L. Houlden
- 1 December 2016
- journal article
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 40 (6) , 484-486
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Pharmacologic Management of Type 2 Diabetes: 2016 Interim UpdateCanadian Journal of Diabetes, 2016
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trialEuropean Heart Journal, 2016
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary SyndromeNew England Journal of Medicine, 2015
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- MethodsCanadian Journal of Diabetes, 2013
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998